1. Home
  2. BJDX vs INM Comparison

BJDX vs INM Comparison

Compare BJDX & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bluejay Diagnostics Inc.

BJDX

Bluejay Diagnostics Inc.

N/A

Current Price

$2.00

Market Cap

2.6M

Sector

Health Care

ML Signal

N/A

Logo InMed Pharmaceuticals Inc.

INM

InMed Pharmaceuticals Inc.

N/A

Current Price

$0.83

Market Cap

2.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BJDX
INM
Founded
2015
1981
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6M
2.7M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
BJDX
INM
Price
$2.00
$0.83
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
111.9K
74.9K
Earning Date
06-15-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
86.65
N/A
EPS
N/A
N/A
Revenue
$249,040.00
$4,942,633.00
Revenue This Year
N/A
N/A
Revenue Next Year
$55.56
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
7.50
52 Week Low
$0.63
$0.73
52 Week High
$10.20
$7.98

Technical Indicators

Market Signals
Indicator
BJDX
INM
Relative Strength Index (RSI) 46.41 42.45
Support Level $1.43 $0.73
Resistance Level $2.47 $0.95
Average True Range (ATR) 0.16 0.08
MACD -0.05 0.01
Stochastic Oscillator 48.98 30.75

Price Performance

Historical Comparison
BJDX
INM

About BJDX Bluejay Diagnostics Inc.

Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay's first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from 'sample-to-result' to help medical professionals make earlier and better triage/treatment decisions.

About INM InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.

Share on Social Networks: